Kezar Life Sciences Inc. (NASDAQ: (KZR) stock plunged by 0.92% at the last close whereas the KZR stock price gains by 5.12% in the pre-market trading session. Kezar Life Sciences is a clinical-stage pharmaceutical firm dedicated to researching and developing novel therapies for immune-mediated and oncologic diseases. The business is developing first-of-its-kind small-molecule medicines that use master regulators of cellular activity to target many disease causes with a single, potent target.
KZR stock’ Recent Past Development
Gitanjali Jain has been named Vice President, Investor Relations and External Affairs at Kezar Life Sciences. Ms. Jain will oversee Kezar’s entire investor relations, public affairs, and scientific communications initiatives as a part of the management team and executive board.
John Fowler, Co-founder, and CEO of Kezar Life Sciences stated,
They are delighted to welcome Gita to the company as they endeavor to provide innovative therapeutics to people suffering from difficult conditions. Gita’s excellent ties with investors and track record of success in the industry will be extremely valuable to Kezar, and he is excited to work with her.
Ms. Jain commented,
She is thrilled to be joining Kezar at such an exciting time in the company’s development of KZR-616. It is the first-in-class immunoproteasome inhibitor, and KZR-261 is the first-in-class protein secretion inhibitor. She is thrilled to be able to add to the team and to Kezar’s growth prospects as they endeavor to develop treatments that address high unmet patient needs.
Furthermore,
Gita joins the company with the expertise of more than 15 years. Before joining Kezar, Gita was working as the Managing Director at Solebury Trout and has provided her key services to more than 50 pharmaceutical companies mainly based on corporate strategy, investor relations, communication, and capital market transactions. She formerly worked as a research associate at Medarex and StemCells, Inc. in the lab. Gita possesses an M.A. in Biology from New York University and a B.A. in Economics from Brown University, as well as a FINRA Series 7, 63, and 79 Financial and Operations Principal license.
